Vantage logo

Immunogen fails to leap Forward

As doubts grow about targeting the folate receptor, Immunogen’s decision to press on with mirvetuximab soravtansine looks desperate.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.